MH

Risk Factors for Malignant Hyperthermia

  • 1 in 100,000 surgical procedures in adults. 1 in 30,000 surgeries in children. Basically, more common in children.

  • Key risk factors include:

    • Family history of MH

    • Young boys (Children under 15 years comprise 52% of all reactions)

    • Geographic location impacts risk: Wisconsin, Nebraska, West Virginia, Michigan

Pathophysiology of MH

  • Inherited, autosomal dominant disorder affecting skeletal muscle characterized by impaired regulation and maintenance of calcium levels.

    • **non-depolarizers are not the best choice for tx as you are not treating the main cause.

  • Associated with 34 genetic mutations primarily linked to the RYR1 (ryanodine) gene.

    • The RYR1 gene encodes the ryanodine receptor, the major calcium release channel. Defective ryanodine receptors lead to excessive calcium release from the sarcoplasmic reticulum (sarcolemma) into the cell.

    • The SERCA2 pump's attempt to return excess calcium to the sarcoplasmic reticulum.

    • Breakdown of the sarcolemma allows potassium and myoglobin (toxic to kidneys) to enter systemic circulation (Aka, rhabdomyolysis occurs).

    • Summary: Massive outflow Ca —> sustained muscle contraction —> hypermetabolism (as the body tries to pump it back into the cell) —> sarcolemma de-stability (cell membrane failure) —> myoglobin/potassium leakage —> Cardiac arrest

  • Summary: Consequences of excessive intracellular calcium:

    • Increased muscle rigidity due to sustained contractions.

    • Increased oxygen consumption

    • Increased metabolic rate (hypermetabolism) and rapid ATP depletion.

    • Increased CO₂ and heat production.

    • Overall: respiratory + lactic acidosis

  • **can occur even hours after surgery. You can differentiate from other neuroleptic disorders bc NMBDs will not resolve s/s.

S/S of MH

  • **Unexplained, sudden rise in end tidal CO₂ >55 mm Hg (which cannot be treated by increasing RR)

  • Unexplained tachycardia or arrythmias (cardiac arrest likely d/t hyperkalemia)

  • Masseter muscle or generalized muscle rigidity.

  • Rising patient temperature (late sign)

  • Cola-colored urine (myoglobinuria).

  • Mottled, cyanotic skin.

  • Decreased oxygen saturation (Sao2).

  • Tachypnea.

  • Labile blood pressure

Laboratory Findings

  • Arterial blood gases indicate respiratory and metabolic acidosis.

  • Serum potassium levels >6 mEq/L.

  • Creatine kinase levels >20,000 units/L.

  • Serum myoglobin >170 mcg/L.

  • Urine myoglobin >60 mcg/L.

MH Triggering Agents

  • The two main categories are Volatile anesthetics and Succinylcholine

  • TIVA and N2O does NOT cause MH

Preparation for MH Susceptible Patients

  • Conduct a thorough preoperative evaluation to identify risks:

    • Family history of unexpected complications, high fever, or death.

    • hx of muscle rigidity under anesthesia.

    • Dark-colored urine after exercise or surgery.

    • Hx of central core disease, King Denborough syndrome, or multi mini core disease.

  • Consider alternatives to general anesthesia: Regional and TIVA anesthetics.

  • Remove any trace has from the machine (even if not using!):

    • Change CO₂ absorbent.

    • Remove or tape off vaporizers.

    • Flush the machine with a new circuit and fresh gas flows exceeding 10 L/min for 20-90 minutes

    • Apply charcoal filters.

Treatment for MH

  • Immediate actions:

    • #1: Discontinue the triggering agent. Use an ambu bag until the entire circuit is changed out.

      • Remember that MH is a self-sustaining chemical reaction, so it must be reversed!

    • Call for help and utilize the MH crisis hotline.

  • Medication protocol:

    • Administer Dantrolene at a dose of 2.5 mg/kg, repeating every 5-10 minutes until symptoms cease.

    • Continuation of Dantrolene in ICU for a minimum of 24 hours at 1 mg/kg every 4 hours as a bolus or 0.25 mg/kg/hr for continuous infusion.

  • Hyperventilation with 100% oxygen at flows >10L/min to improve oxygenation and decrease CO₂ levels.

  • Laboratory tests required: Coagulation profile, ABGs, electrolytes, CK, and myoglobin and liver enzymes.

  • Cooling of the patient: Administer IV fluids and apply ice packs to the groin, axilla, and neck. However, stop cooling at 38 C to prevent hypothermia

  • Tx arrhythmias: Avoid calcium channel blockers. You can use amio if needed.

    • CCBs such as verapamil can further cause hyperkalemia if given to a patient who also received dantrolene!

  • Treatment for hyperkalemia: hyperventilation, bicarbonate (1-2 mEq/kg), intravenous insulin/glucose, calcium chloride (10 mg/kg), albuterol, diuresis

  • Maintain hydration with a urine output goal of >1 ml/kg/hour (d/t rhabdo effects)

Dantrolene (Dantrium/Revonto) or Ryanodex Medications for MH

  • MOA: Acts directly on skeletal muscle by Binding to ryanodine receptors to inhibit calcium efflux from the sarcoplasmic reticulum

    • Tip: treat as quickly as possible because it is a rapid biochemical crisis where seconds = muscle cells dying

  • MHAUS recommends either drug version to be immediately available at all times:

    • Dantrolene (Dantrium/Revonto): 20 mg vials, stocked to a minimum of 36 vials. Each bottle contains 3 g of mannitol and must be diluted with 60 ml of sterile WATER, shaken vigorously until clear due to poor solubility (very hard to mix together).

      • **mannitol is added for 1) diuresis effects since pt will have rhabdomyolsis and 2) increase solubility of the dantrolene powder to try and help make it more mixable with liquid

    • Ryanodex is 250 mg vial, stocked to minimum of x3 vials (MUCH more expensive). Each bottles contains 0.125 g mannitol and must be diluted with 5 mL of sterile WATER. A little easier to mix than dantrolene, but still hard.

  • Adverse effects of dantrolene:

    • Muscle weakness.

    • Hepatotoxicity.

    • CNS depression.

    • Myocardial depression.

Diagnostic Testing for MH

  • The most accurate and accepted test is the Caffeine Halothane Contracture Test (CHCT).

    • Availability: Only at 5 medical centers in North America.

    • Costs: $6,000 or more, and insurance may not cover it.

    • Patients must travel to testing centers as the muscle biopsy needs to be fresh.

  • Genetic testing for RYR1, CACNA1S, or STAC3 gene mutations is a less expensive alternative but has lower accuracy.